BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 8913353)

  • 1. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
    Pak Y; Kouvelas A; Scheideler MA; Rasmussen J; O'Dowd BF; George SR
    Mol Pharmacol; 1996 Nov; 50(5):1214-22. PubMed ID: 8913353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.
    Xu H; Lu YF; Rothman RB
    Synapse; 2003 Jan; 47(1):1-9. PubMed ID: 12422367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mu-opioid receptor down-regulates differently from the delta-opioid receptor: requirement of a high affinity receptor/G protein complex formation.
    Chakrabarti S; Yang W; Law PY; Loh HH
    Mol Pharmacol; 1997 Jul; 52(1):105-13. PubMed ID: 9224819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
    Puttfarcken PS; Werling LL; Cox BM
    Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
    He L; Lee NM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells.
    Prather PL; Tsai AW; Law PY
    J Pharmacol Exp Ther; 1994 Jul; 270(1):177-84. PubMed ID: 8035314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY; Yang HH; Li S; Adams JU
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
    Xu H; Wang X; Wang J; Rothman RB
    Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
    Traynor JR; Nahorski SR
    Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
    Minami M; Nakagawa T; Seki T; Onogi T; Aoki Y; Katao Y; Katsumata S; Satoh M
    Mol Pharmacol; 1996 Nov; 50(5):1413-22. PubMed ID: 8913373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells.
    Baumhaker Y; Gafni M; Keren O; Sarne Y
    Mol Pharmacol; 1993 Aug; 44(2):461-7. PubMed ID: 8394999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible modulation of opioid receptor binding in intact neural cells by endogenous guanosine triphosphate.
    Yabaluri N; Medzihradsky F
    Mol Pharmacol; 1995 Oct; 48(4):690-5. PubMed ID: 7476895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling.
    Yabaluri N; Medzihradsky F
    Mol Pharmacol; 1997 Nov; 52(5):896-902. PubMed ID: 9351981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sections.
    Martin TJ; Sim LJ; Selley DE; deMontis MG; Childers SR
    Synapse; 1997 Nov; 27(3):177-82. PubMed ID: 9329153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
    Clark MJ; Traynor JR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus.
    Selley DE; Liu Q; Childers SR
    J Pharmacol Exp Ther; 1998 May; 285(2):496-505. PubMed ID: 9580589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential coupling of mu-, delta-, and kappa-opioid receptors to G alpha16-mediated stimulation of phospholipase C.
    Lee JW; Joshi S; Chan JS; Wong YH
    J Neurochem; 1998 May; 70(5):2203-11. PubMed ID: 9572309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.